The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized controlled trial (RCT) of symptom screening with targeted early palliative care (STEP) versus usual care in patients with advanced cancer.
 
Camilla Zimmermann
No Relationships to Disclose
 
Ashley Pope
No Relationships to Disclose
 
Breffni Hannon
No Relationships to Disclose
 
Monika K. Krzyzanowska
Consulting or Advisory Role - Eisai; Lilly
Research Funding - Eisai (Inst); Exelixis (Inst); Lilly (Inst)
 
Gary Rodin
No Relationships to Disclose
 
Madeline Li
No Relationships to Disclose
 
Doris Howell
No Relationships to Disclose
 
Jennifer J. Knox
Honoraria - AstraZeneca; Roche Canada
Consulting or Advisory Role - AstraZeneca/MedImmune; Incyte; Ipsen; Lilly; Merck
Research Funding - AstraZeneca; Ipsen; Merck
Expert Testimony - AstraZeneca
 
Natasha B. Leighl
Research Funding - Amgen (Inst); AstraZeneca Canada (Inst); Bayer (Inst); EMD Serono (Inst); Guardant Health (Inst); Lilly (Inst); MSD (Inst); MSD Oncology (Inst); Roche Canada (Inst); Roche Canada (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Pfizer (Inst)
 
Amit M. Oza
(OPTIONAL) Uncompensated Relationships - Ozmosis Research
 
Rebecca M. Prince
Honoraria - Eisai
 
Stephanie Lheureux
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Novartis; Novartis; Novocure; Shattuck Labs
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Tesaro (Inst)
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)
 
Neesha C. Dhani
Honoraria - AstraZeneca
 
Geoffrey Liu
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Jazz Pharmaceuticals; Merck; novartis; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca; Pfizer; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; roche (Inst); Takeda
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Gilead Sciences; Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
 
Eric Xueyu Chen
Honoraria - AstraZeneca Canada; Bayer; Eisai; Ipsen; Roche Canada
Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Nubiyota; Repare Therapeutics; Roche Canada
 
Nadia Swami
No Relationships to Disclose
 
Lisa W Le
No Relationships to Disclose